Voyager Therapeutics, Inc. $VYGR

What the company doesAI summary of filing

Voyager Therapeutics is a biotechnology company developing gene therapies and other genetic medicines for neurological diseases, primarily Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, and other central nervous system disorders. The company is pre-revenue and advancing a pipeline of wholly-owned programs (including VY1706, a tau silencing gene therapy, and VY7523, an anti-tau antibody for Alzheimer's disease) and collaborative programs with partners including Neurocrine Biosciences, Novartis, Alexion, and Transition Bio. The company generates revenue through non-dilutive funding from partnerships, having received over $500 million to date in upfront fees, milestone payments, and research funding, with potential to earn up to $6.8 billion in future milestone payments and royalties. Voyager's programs leverage its TRACER platform, a discovery technology enabling development of adeno-associated virus capsids designed to cross the blood-brain barrier and deliver genetic medicines intravenously. [10-K 2026-03-09]

Segments: VY1706 (Tau Silencing Gene Therapy for Alzheimer's Disease), VY7523 (Anti-Tau Antibody for Alzheimer's Disease), Friedreich's Ataxia Program (with Neurocrine), GBA1 Gene Therapy Program for Parkinson's Disease and Gaucher Disease (with Neurocrine)